These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 22951239

  • 21. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
    Tobin M.
    Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170
    [No Abstract] [Full Text] [Related]

  • 22. Transdermal selegiline.
    Patkar AA, Pae CU, Zarzar M.
    Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
    [Abstract] [Full Text] [Related]

  • 23. Reversible monoamine oxidase-A inhibitors in resistant major depression.
    Nolen WA, Hoencamp E, Bouvy PF, Haffmans PM.
    Clin Neuropharmacol; 1993 Jun; 16 Suppl 2():S69-76. PubMed ID: 8313400
    [Abstract] [Full Text] [Related]

  • 24. Monoamine oxidase-inhibiting antidepressants. A clinical update.
    Murphy DL, Sunderland T, Cohen RM.
    Psychiatr Clin North Am; 1984 Sep; 7(3):549-62. PubMed ID: 6384960
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Chen JJ, Wilkinson JR.
    J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Translating the evidence on atypical depression into clinical practice.
    Hyman Rapaport M.
    J Clin Psychiatry; 2007 May; 68 Suppl 3():31-6. PubMed ID: 17348765
    [Abstract] [Full Text] [Related]

  • 32. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants.
    Stahl SM, Felker A.
    CNS Spectr; 2008 Oct; 13(10):855-70. PubMed ID: 18955941
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures.
    Pae CU, Bodkin JA, Portland KB, Thase ME, Patkar AA.
    J Clin Psychiatry; 2012 May; 73(5):661-8. PubMed ID: 22697192
    [Abstract] [Full Text] [Related]

  • 35. Dietary tyramine and other pressor amines in MAOI regimens: a review.
    McCabe BJ.
    J Am Diet Assoc; 1986 Aug; 86(8):1059-64. PubMed ID: 3525654
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
    Robinson DS, Amsterdam JD.
    J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687
    [Abstract] [Full Text] [Related]

  • 40. [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression].
    Nolen WA.
    Ned Tijdschr Geneeskd; 2003 Oct 04; 147(40):1940-3. PubMed ID: 14574774
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.